Sponsors (8)
Directs and prioritizes expanded NIH research, training, and a 24-month PKD research and innovation roadmap with benchmarks and collaboration strategies.
The bill focuses federal research and coordination to accelerate PKD diagnostics, treatments, and clinical capacity—potentially improving care for hundreds of thousands of Americans—while raising risks of higher federal spending, diversion of other research priorities, data/IP conflicts, and possible policy responses that could tighten coverage for costly care.
People with polycystic kidney disease (PKD) are likely to get faster development and earlier access to new diagnostics and treatments because the bill expands NIH-funded basic, translational, and clinical research and promotes coordinated public–private commercialization pathways (including AI and precision‑medicine approaches).
Researchers, clinicians, and hospitals will have more training and specialization opportunities in PKD care, strengthening the clinical workforce and improving patient care capacity.
Medicare beneficiaries with PKD are identified as a high‑cost population, which can justify targeted federal programs or resource allocation aimed at preventing progression to dialysis/transplant and lowering long‑term Medicare spending.
Medicare beneficiaries and people needing dialysis/transplant could face tighter coverage rules or cost‑containment policies (including prior authorization) if policymakers emphasize cutting the roughly $3 billion PKD‑related Medicare costs rather than expanding care.
Expanding NIH priorities and new federally coordinated PKD initiatives will likely increase federal research spending and could crowd out other research areas or add pressure on taxpayers.
Public–private research collaborations promoted by the bill could create conflicts over data access, intellectual property, and trial design that limit patient access, raise costs, or complicate implementation.
Based on analysis of 3 sections of legislative text.
Official title: To support polycystic kidney disease research, and for other purposes.
Introduced June 4, 2026 by Debbie Wasserman Schultz · Last progress June 4, 2026
Creates a coordinated, expanded NIH research program focused on polycystic kidney disease (PKD). It requires the NIH and the relevant institute to prioritize basic, translational, and clinical PKD research, support training, collaborate with partners, and produce a public roadmap with timelines and recommendations within 24 months. Directs the NIH Director to convene a working group to identify research gaps and priorities, recommend public–private collaboration strategies, propose benchmarks and timelines, and report findings and an innovation roadmap to Congress within two years.